Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2− Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies

par Abeer J. Al-Qasem, Carla L. Alves, Henrik J. Ditzel
Publié 2021

Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes

par Mikkel G. Terp, Odd L. Gammelgaard, Henriette Vever, Morten F. Gjerstorff, Henrik J. Ditzel
Publié 2021

On the performance of de novo pathway enrichment

par Richa Batra, Nicolas Alcaraz, Kevin Gitzhofer, Josch Pauling, Henrik J. Ditzel, Marc Hellmuth, Jan Baumbach, Markus List
Publié 2017

Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study.

par Maria B Lyng, Anne-Vibeke Lænkholm, Qihua Tan, Werner Vach, Karina H Gravgaard, Ann Knoop, Henrik J Ditzel
Publié 2013

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells

par Mikkel G. Terp, Kirstine Jacobsen, Miguel Angel Molina, Niki Karachaliou, Hans C. Beck, Jordi Bertran-Alamillo, Ana Giménez-Capitán, Andrés F. Cardona, Rafael Rosell, Henrik J. Ditzel
Publié 2021

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

par Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Publié 2021

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

par Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Publié 2021

EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy

par Yi Bao, Gokce Oguz, Wee Chyan Lee, Puay Leng Lee, Kakaly Ghosh, Jiayao Li, Panpan Wang, Peter E. Lobie, Sidse Ehmsen, Henrik J. Ditzel, Andrea Wong, Ern Yu Tan, Soo Chin Lee, Qiang Yu
Publié 2020

Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells

par Alexei F. Kirkin, Karine N. Dzhandzhugazyan, Per Guldberg, Johnny Jon Fang, Rikke S. Andersen, Christina Dahl, Jann Mortensen, Tim Lundby, Aase Wagner, Ian Law, Helle Broholm, Line Madsen, Christer Lundell-Ek, Morten F. Gjerstorff, Henrik J. Ditzel, Martin R. Jensen, Walter Fischer
Publié 2018

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

par Kirstine Jacobsen, Jordi Bertran-Alamillo, Miguel Angel Molina, Cristina Teixidó, Niki Karachaliou, Martin Haar Pedersen, Josep Castellví, Mónica Garzón, Carles Codony-Servat, Jordi Codony-Servat, Ana Giménez-Capitán, Ana Drozdowskyj, Santiago Viteri, Martin R. Larsen, Ulrik Lassen, Enriqueta Felip, Trever G. Bivona, Henrik J. Ditzel, Rafael Rosell
Publié 2017

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

par Sanne Løkkegaard, Daniel Elias, Carla L. Alves, Martin V. Bennetzen, Anne-Vibeke Lænkholm, Martin Bak, Morten F. Gjerstorff, Lene E. Johansen, Henriette Vever, Christina Bjerre, Tove Kirkegaard, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Linda S. Lindström, Laura J. Esserman, Anne E. Lykkesfeldt, Jens S. Andersen, Rikke Leth-Larsen, Henrik J. Ditzel
Publié 2021